HR
TARA icon

Howe & Rusling’s Protara Therapeutics TARA Stock Holding History

Howe & Rusling’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1
Closed – – 1116
2016
Q2 		$0 Hold
1
– – ﹤0.01% 1045
2016
Q1 		$0 Hold
1
– – ﹤0.01% 1054
2015
Q4 		$1K Hold
1
– – ﹤0.01% 939
2015
Q3 		$1K Hold
1
– – ﹤0.01% 955
2015
Q2 		$1K Buy
+1
New +$619 ﹤0.01% 979

Other funds holding TARA

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
DVC
Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
TAM
Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Howe & Rusling's TARA Position: Q3 2016 in Review

Howe & Rusling sold out of Protara Therapeutics (TARA) in Q3 2016, closing a stake of 1 share.

Howe & Rusling first reported a position in TARA in Q2 2015 and held it in 5 quarters. The position peaked at $1K in Q4 2015. 29 funds tracked by Wall St. Rank hold TARA as of Q3 2016.

  • Howe & Rusling reported no remaining Protara Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Howe & Rusling sold 1 Protara Therapeutics share in Q3 2016.
  • Howe & Rusling first reported a position in Protara Therapeutics in Q2 2015 and held it in 5 quarters.
  • Howe & Rusling's Protara Therapeutics position peaked at $1K in Q4 2015.
  • 29 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2016.

Based on Howe & Rusling's 13F filing for Q3 2016, filed 17 Oct 2016.